Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Nippon Shinyaku

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Nippon Shinyaku's Japan sales performance.

nippon

FDA sets Q3 decision date for NS Pharma’s DMD drug

FDA sets Q3 decision date for NS Pharma’s DMD drug

NS Pharma and its parent company Nippon Shinyaku are currently enrolling patients for a phase 3 study in Japan and the US – named RACER53.

Wave’s challenge to Sarepta in Duchenne falls flat

Wave’s challenge to Sarepta in Duchenne falls flat The demise of Wave’s programmes leaves Japan’s Nippon Shinyaku Pharma as the main rival to Sarepta in DMD.

Solid Bio falls as FDA halts DMD trial over safety concerns

Solid Bio falls as FDA halts DMD trial over safety concerns In the meantime, rival candidate viltolarsen from Japanese pharma Nippon Shinyaku (NS Pharma) has been  filed with the FDA for the treatment of DMD.

Sarepta rival NS Pharma files Duchenne drug with FDA

Sarepta rival NS Pharma files Duchenne drug with FDA Another blow for Sarepta following FDA rejection earlier this year. Japanese pharma Nippon Shinyaku (NS Pharma) has announced its candidate for Duchenne musuclar dystrophy (DMD) has been submitted to the FDA

Biosimilar Remicade reaches market in Japan and India

Biosimilar Remicade reaches market in Japan and India India. In Japan, Nippon Kayaku has launched a biosimilar version of Remicade (infliximab) originally developed by South Korean biotechnology company Celltrion, which was approved for marketing in July. ... Nippon Kayaku said infliximab is the second

1 2 3 4 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
JPA Health Communications

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics